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With growing understanding of the relationship between diet and health has come the 2 
emergence of so-called functional foods. The idea of using food for health purposes and not merely 3 
as a source of nutrients opens up a whole new field in the meat industry. In addition to traditional 4 
presentations, there a number of ways in which the meat sector can modify the qualitative and 5 
quantitative composition of meat and meat product components and produce designer foods with 6 
specific properties. This entails addressing quality factors associated with different product 7 
properties (sensory and technological properties, hygiene, convenience, stability, etc.), nutritional 8 
value (balanced composition and bioactive substances) and their effects on physiological function 9 
and health. This article reviews a comprehensive model for the development of meat-based 10 
functional foods based on a presentation of the research achieved in terms of the design and 11 
development of qualitatively and quantitatively modified meat products (through reformulation) in 12 
nutrients associated with cardiovascular risk (walnut as a source of bioactive substances). It also 13 
discusses their bioavailability and the effect of their consumption on intermediate cardiovascular 14 
risk markers in humans.  15 
 16 
 17 
Key words: Functional food; meat products, walnut, technological development; bioavailability; 18 
cardiovascular disease risk  19 
 20 
Short title: Walnut-enriched meat as a functional food 21 
 3
1. Introduction 22 
Growing understanding of the relationship between diet and health is leading to new 23 
insights into the effect of food ingredients on physiological function and health, inducing increased 24 
consumer demand for healthy, nutritious foods with additional health promoting functions, such as 25 
functional foods.  26 
Over the last several decades, meat products have come under increasing scrutiny by 27 
medical, nutritional and consumer groups because of the associations established between their 28 
consumption (or that of a number of their constituents—fat, cholesterol, etc.) and the risk of some 29 
of the major degenerative and chronic diseases (ischemic heart disease, cancer, hypertension and 30 
obesity). Therefore, meat-based functional foods are being seen as an opportunity to improve the 31 
“image” of meat and address consumer needs, and also to update the nutritional and dietary goals 32 
(Jiménez-Colmenero, 2007a).  33 
Most research into meat-based functional foods has been founded on animal production or 34 
technological strategies to increase the presence of healthy compounds (Arihara, 2006; Jiménez-35 
Colmenero, 2007b; Jiménez-Colmenero, Carballo, & Cofrades, 2001; Muguerza, Gimeno, 36 
Ansorena, & Astiasarán, 2004). This article reports a comprehensive approach to the design and 37 
development of reformulated meat-based functional foods in which animal fat is reduced and 38 
bioactive compounds (walnut) are added in appropriate amounts to achieve a functional effect. This 39 
functional effect was assessed by means of an intervention study with volunteers presenting 40 
increased risk of cardiovascular disease. 41 
      42 
2. Dietary intake and cardiovascular diseases (CVD) 43 
Diet and nutrition are important factors in the promotion and maintenance of health 44 
throughout life. According to the World Health Organization (WHO) and the Food and Agriculture 45 
Organization (FAO), several dietary patterns along with lifestyle habits constitute major modifiable 46 
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risk factors in relation to the development of  non-communicable diseases, coronary heart disease 47 
(CHD), cancer, type 2 diabetes, obesity, osteoporosis and periodontal disease (WHO, 2003). In 48 
addition to providing nutrients to cover metabolic requirements, diet can modify specific 49 
physiological functions and reduce the risk of certain diseases. Chronic diseases contribute to 50 
approximately 60% of deaths, almost half of which are cardiovascular (WHO, 2003). Moreover, 51 
deaths and disabilities due to CHD and strokes can be cut by more than 50% by a combination of 52 
simple and effective low-cost national efforts and individual actions to reduce major risk factors 53 
such as high blood pressure, high cholesterol, obesity and smoking (WHO, 2007).   54 
According to the WHO (2009), by 2010 CVD will be the leading cause of death in 55 
developing countries, as these are no longer only diseases of the developed world. The rise in CVD 56 
reflects a significant change in dietary habits, physical activity levels, and tobacco consumption 57 
worldwide as a result of industrialization, urbanization, economic development and food market 58 
globalization. For instance, people nowadays consume a more energy-dense, nutrient-poor diet and 59 
are less physically active. Imbalanced nutrition, reduced physical activity and increased tobacco 60 
consumption are the key lifestyle factors. High blood pressure, high blood cholesterol, overweight 61 
and obesity—and type 2 diabetes—are among the major biological risk factors in CVD. Unhealthy 62 
dietary practices include high consumption of saturated fats, salt and refined carbohydrates and low 63 
fruit and vegetable intake (WHO, 2003; WHO, 2009), whereas recommendations concerning the 64 
reduction of CVD risk in industrialized countries commonly specify less fat (total, saturated and ω-65 
6 polyunsaturated—PUFAs—fatty acids and non-trans) (WCRF/AICR, 1997; WHO, 2003). 66 
 67 
3. Functional foods. 68 
Observations associating particular eating habits, mainly excessive intake of certain 69 
nutrients, with the etiology and development of chronic diseases have led to the concept of 70 
“optimal nutrition”. Optimal nutrition is based on a number of dietary recommendations to modify 71 
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(reduce or increase) the intake of certain foods or food components and the development of new 72 
foods in which the original composition is modified, in terms of both nutrient and non-nutrient 73 
contents. The ultimate aim is to optimize physiological functions and so maximize their 74 
contribution to well-being and health and minimize the risk of diseases. It is in this context that 75 
functional foods come to the fore. A food may be regarded as functional if it is satisfactorily 76 
demonstrated that it beneficially affects one or more target functions in the body, over and above 77 
adequate nutritional effects, in a way that is relevant to either an improved state of health and well-78 
being and/or a reduction of the risk of disease. A functional food can be a natural food, or a food to 79 
or from which a component has been added or removed by technological or biotechnological means 80 
(Diplock, et al., 1999). The incorporation of these products into the diet is highly desirable and 81 
could have considerable public health implications, not only because it can reach broad population 82 
groups but also because these diseases start at early ages and because they entail a high cost to 83 
society and governments in financial terms and in terms of disability-adjusted life years. 84 
 The criteria required to assess the scientific basis of claims regarding food properties were 85 
laid down in the course of the projects FUFOSE (Diplock et al., 1999) and PASSCLAIM (Aggett et 86 
al., 2005; Asp et al., 2004). Finally, a consensus was arrived at on the scientific criteria that need to 87 
be followed for purposes of assessment or design of foods for which healthy properties are claimed 88 
(Aggett et al., 2005). Changes in composition are not enough for a food to be considered 89 
functional; it must also be satisfactorily shown that consumption has a beneficial effect on certain 90 
population groups. Trials are therefore necessary to demonstrate such an effect, preferably in 91 
humans and using suitable intermediate biomarkers for early detection and prognosis of the disease 92 
(Aggett et al., 2005).   93 
Where it is not possible to directly measure the effect of a food in terms of health, quality of 94 
life or reduced risk of disease—as in most cases concerning chronic diseases—functionality is 95 
assessed by means of biomarkers. In the field of nutrition, biomarkers should be associated with a 96 
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future health objective, but at a stage where dietary intervention can effectively assist early 97 
diagnosis or improved prognosis of the disease in question. Such markers of intermediate 98 
objectives within the process of the disease must be carefully selected to allow for short-term 99 
measurements that can be used later on to make inferences regarding the effects on final objectives 100 
which would only normally be possible in a long-term study.  101 
  102 
4. Walnut and cardiovascular disease: Bioactive components  103 
Epidemiological studies show that regular consumption of nuts in general, and walnut in 104 
particular (Banel & Hu, 2009; Feldman, 2002; Fitó et al., 2007; Fraser, Sabaté, Beeson, & Strahan, 105 
1992; Iwamoto et al., 2000; Nus, Ruperto, & Sánchez-Muniz, 2004; Sabaté, 1993; Sabate et al.,   106 
1993; Salas-Salvadó, García-Arellano et al., 2008; Salas-Salvadó, Fernández-Ballart, 2008; 107 
Tyrovolas & Panagiotakos, 2009) correlates inversely with myocardial infarction and CHD 108 
regardless of other factors associated with risk such as age, sex, smoking, hypertension, weight and 109 
exercise. Although the exact mechanism is not understood, the positive effects of walnut intake 110 
have been attributed, at least in part, to its particular lipid composition, which is characterized by a 111 
high fat content (62-68 % dry matter) and abundant monounsaturated fatty acids (MUFAs, oleic 112 
acid 18 % of total fatty acids) and PUFAs (linoleic and α-linolenic making up 58 and 12 %, 113 
respectively of total fatty acids). In addition to these, there are other components of interest: fibre 114 
(5-10 % dry matter), protein (14 % dry matter) rich in arginine, vitamins, minerals, phytosterols, 115 
polyphenols, etc. (Nus et al., 2004; Ravai, 1995; Sabaté, 1993; USDA, 2005).  116 
Walnuts have been selected as a potential functional component in meat products because 117 
their nutritional composition has more relevance to CVD than other nuts and plant foods (e.g. ω-6 118 
and ω-3 PUFAs, γ-tocopherol, arginine-rich protein) and because they are generally acceptable to 119 
consumers. In addition, this approach supplies several other constituents of walnuts (e.g. plant 120 
sterols, polyphenols and fibre) without substantially reducing other nutritionally important 121 
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components of meat such as iron and zinc (Olmedilla-Alonso, Granado-Lorencio, Herrero-Barbudo, 122 
& Blanco-Navarro, 2006). The amount of walnuts to be incorporated into the final product is 123 
partially based on nut and meat consumption data in Spain (INE, 1994; MAPA, 2003), data from 124 
epidemiological and clinical studies with nuts, and suggestions about nut intake (FDA, 2003).  125 
In response to the evidence for the beneficial health effect of walnut consumption, stress has 126 
recently been placed on the importance of including them as a regular part of the diet. In this 127 
context the Food and Drug Administration (FDA) has approved the possibility of a qualified health 128 
claim in relation to heart disease. In particular it is permitted to state that “supportive but not 129 
conclusive research shows that eating 1.5 ounces (42.5 g) of walnuts, as part of a low saturated fat 130 
and low cholesterol diet and not resulting in increased caloric intake, may reduce the risk of 131 
coronary heart disease” (FDA, 2003; FDA, 2004). That claim statement on walnuts and heart 132 
disease has been reviewed without changes for whole or chopped walnuts (FDA, 2009). For its 133 
part, the WHO (WHO, 2003) recommends consuming at least 400 g of fruit and vegetables daily, at 134 
least 30 g of which should be nuts, pulses or seeds. In its global strategy programmes for CVD 135 
prevention, the WHO (2009) recommends, among other dietary strategies, consuming a diet rich in 136 
fruit, vegetables, nuts and whole grains.  137 
Despite such notable advantages, walnut consumption generally falls short of recommended 138 
levels. Not many people can be persuaded to systematically consume enough walnuts in their pure 139 
state over long periods of time (every day over a long period). They are more likely to accept dishes 140 
prepared with it. One way to promote walnut intake would be to use it as an ingredient in 141 
frequently-consumed foods, for instance meat derivatives, to which bioactive compounds can be 142 
added to render them more heart-healthy (Jiménez Colmenero et al., 2001; Sánchez-Muniz, 2004). 143 
 144 
5. Meat products as functional foods 145 
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Meat and meat products are essential parts of the diet which concentrate and supply a large 146 
number of nutrients (protein, fat, vitamins, minerals). Meat is a fundamental source of proteins of 147 
high biological value. It is a well-balanced source of amino acids that satisfies human physiological 148 
requirements. Meat is a good source of iron, zinc and phosphorus, with significant amounts of other 149 
essential trace elements such as selenium, magnesium and cobalt, and an excellent source of B 150 
group vitamins like B1, B2, niacin, pantothenic acid, vitamin B6 and vitamin B12 (Jiménez-151 
Colmenero, 2007a). Meat has traditionally been highly appreciated as a food of great nutritional 152 
value, and meat consumption has always been associated with good health and prosperity. 153 
However, over the last few years the situation has changed, among other reasons because of the 154 
epidemiological associations discovered between meat and meat derivatives or some of their 155 
constituents, and the risk of some of the major diseases in our society (CHD, cancer, high blood 156 
pressure and obesity). Like other food-related sectors, the meat industry is in a permanent state of 157 
change in response to continuous technological innovations and changes in consumer demands, 158 
among which those relating to improvement of certain health-related aspects through the diet are 159 
becoming increasingly important. This situation is prompting the emergence of new, “healthier” 160 
meat products, prominent among them functional foods, which are the main driving force behind 161 
the development of new food products, including meat-based products. Functional meat derivatives 162 
present an excellent opportunity to diversify and take up positions in a tremendously important 163 
emerging market (Jiménez-Colmenero, Reig, & Toldrá, 2006). 164 
There are various strategies for introducing qualitative and/or quantitative modifications in 165 
meat and meat derivatives in order to achieve a “functional” product, and of these, strategies 166 
associated with meat processing are especially promising. The principal advantage of meat 167 
derivatives in terms of modifying composition is the opportunity that they offer to change the 168 
ingredients (meat and non-meat) used to produce them and hence work with various endogenous 169 
and exogenous bioactive compounds. The basic idea is to be able to limit the concentration of 170 
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compounds with adverse physiological effects and enhance the concentration of other, beneficial 171 
ones (Jiménez Colmenero et al., 2001; Jiménez-Colmenero, 2007a; Sánchez-Muniz, 2004). Most 172 
physiologically active substances come from plants, and when combined with other foods such as 173 
meat derivatives they can help endow a food with functional effects. The idea of using plant 174 
products in the meat industry is not a new one; various types of ingredients have been used for their 175 
technological, sensory, economic and nutritional effects. Because of their importance, lipids are 176 
among the bioactive components that have received most attention, particularly (in quantitative and 177 
qualitative terms) with respect to the development of potential meat-based functional foods 178 
(Jiménez-Colmenero, 2007b). In that respect, the special characteristics of walnuts offer promising 179 
perspectives for the development of functional meat products. As one of the most important 180 
commonly-consumed foods, meat offers excellent ways to promote intake of functional ingredients 181 
without any radical changes in eating habits. 182 
 183 
6. Design of meat-based functional foods with walnuts 184 
Within this context and considering the present state of and trends in meat consumption, our 185 
team has embarked on the design and development of walnut-enriched functional meat-based 186 
products with potential for CHD risk reduction. Within a multidisciplinary project, we address the 187 
development of a functional meat product of this type using reformulation technology. Specifically, 188 
our aim is to design and develop meat products qualitatively and quantitatively modified in such a 189 
way as to achieve a nutrient composition profile associated with a reduced risk of CHD (Olmedilla-190 
Alonso et al., 2006).  191 
The proposed design incorporates some of the strategies that are known to be effective in 192 
preventing CHD (WHO, 2009), such as: limiting energy intake from total fats and shifting fat 193 
consumption away from saturated fats to unsaturated fats and towards the elimination of trans-fatty 194 
acids; increasing consumption of ω-3 PUFAs from fish oil or plant sources; consuming a diet rich 195 
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in fruits, vegetables, nuts and whole grains, and low in refined grains; avoiding excess consumption 196 
of food with high content of salt and refined carbohydrates. The dietary intake of fats, and 197 
especially their quality, strongly influences the risk of CVD like coronary heart disease and stroke, 198 
through effects on blood lipids, thrombosis, blood pressure, arterial function, arrhythmogenesis and 199 
inflammation. Excess salt has a significant impact on blood pressure levels (WHO, 2009). 200 
For this purpose, several aspects had to be addressed: how much meat could be supplied to 201 
be acceptable and sustainable within a balanced diet while being compatible with nutritional 202 
recommendations based on the available scientific evidence, which nut(s) and what amounts should 203 
and could be incorporated into the final meat product (technological challenge); and, finally, how to 204 
assess the efficacy of the product for the purpose for which it had been developed (human 205 
intervention trial and use of biomarkers). Walnuts were selected as a good source of nutrients 206 
relevant to CVD (e.g. ω-6 and ω-3 PUFAs, γ-tocopherol, arginine-rich protein) compared to other 207 
nuts and plant foods. The amount of walnuts and meat to be consumed was based on nut and meat 208 
consumption data in Spain (INE, 1994; MAPA, 2003) and recommendations about nut intake (e.g. 209 
FDA, 2003; Olmedilla-Alonso et al., 2006). It was thought necessary to formulate at least two types 210 
of walnut-enriched meat products (for reasons of diversification), which could reasonably be 211 
consumed by a large percentage of the population five times a week as part of a normal diet and 212 
sustained over the long term. The study was designed to last five weeks, time enough to be sure of 213 
a change in lipid profile following the dietary intervention.  214 
The meat-based functional products had to contain a high concentration of walnut, and 215 
therefore they were designed so that 150 g of any of them would supply ca. 70 % of the daily 216 
walnut intake recommended to help reduce the risk of cardiovascular diseases (FDA, 2003). That is 217 
equivalent to consuming 19.4 g walnut/day. This proposal required a reformulation of meat 218 
derivatives involving compositional changes that affect protein quality, lipid content and profile, 219 
and the presence of antioxidants. 220 
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The approach to the technological and nutritional challenges and physiological testing used 221 
in the study reported below may be fully applicable to the development of other functional food 222 
products. 223 
 224 
7. Technological development of meat products with added walnut  225 
One fundamental aspect of this research is the technological development of meat products 226 
formulated with walnut, which must achieve comparable quality levels (sensory, nutritional, 227 
technological, health, convenience, etc.) to those of any other meat product of similar 228 
characteristics. This also includes other aspects (social, legal, etc.) unrelated to the intrinsic quality 229 
of the product which affect their valuation and degree of acceptance. In accordance with the design, 230 
the manufacturing process was aimed at both limiting concentrations of certain unwanted 231 
compounds (animal fat, sodium) and promoting the presence of bioactive compounds (present in 232 
the added walnut) with potentially beneficial effects on the onset and development of 233 
cardiovascular disorders.  234 
Based on strategies of this kind, two types of product were developed with clearly different 235 
characteristics: restructured steaks and frankfurters (gel/emulsion systems). These kinds of 236 
products were chosen for their special interest. Restructured steaks belong to a range of foods 237 
which offer major advantages in industrial terms and can readily satisfy all consumer requirements 238 
(appearance, composition, texture, constant quality, convenience, etc.). Then frankfurters belong to 239 
a group of derivatives of major economic importance which are widely accepted throughout the 240 
world. 241 
The technological approach, manufacturing and preparation procedures, physicochemical 242 
and sensory characteristics, storage stability and cooking behaviour of  the new derivatives were 243 
evaluated. Following is a brief account of the studies carried out, highlighting the impact of various 244 
variables on the physicochemical and sensory characteristics of the products as influenced by 245 
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various factors assayed in the technological manufacturing processes. 246 
 247 
7.1 Restructured steaks 248 
One essential aspect of this research was analysis of the influence of the percentage of 249 
added walnut (0, 5, 10 and 20 %) on the characteristics of the protein matrix (physicochemical 250 
properties, microstructure) and sensory attributes of restructured steaks (Cofrades et al., 2004a; 251 
Jiménez-Colmenero et al. 2003; Serrano, Cofrades, & Jiménez-Colmenero, 2004). Although adding 252 
walnut produces certain changes in the matrix, the resulting products presented acceptable 253 
physicochemical and sensory characteristics. One of the conditioning factors analysed was the 254 
effect of the degree of structural disintegration of the meat on the influence of added walnut on 255 
product characteristics (Cofrades et al., 2004a). Restructured steaks were formulated with walnut 256 
using thermal gelation and cold gelation with microbial transglutaminase. Thermal gelation was 257 
used to evaluate the consequences of changing the formulation for purposes of marketing as a 258 
frozen product (Jiménez Colmenero et al., 2003) or a pre-cooked product (Cofrades et al., 2004b). 259 
Cold gelation procedures were used to make steaks containing different concentrations of walnut 260 
(0, 10 and 20%) for chilled storage (Serrano et al., 2004).  261 
In order to improve the outward appearance of the restructured steaks, a number of protein 262 
coatings were assayed. The idea was, once the steak was made, to coat it with a protein film that 263 
would lend it the appearance of a conventional steak. The development of the product, the 264 
application and technology of the coating preparation and various other aspects reported in this 265 
article are all protected by patent (Spanish Patent Application Nº 200300367; Spanish Patent 266 
Application Nº 200400548). 267 
The reformulation of meat products to enhance health-beneficial components, as in the case 268 
of added walnut, produces qualitative and quantitative changes in the composition (protein, lipids 269 
and others components) of meat products (Serrano et al. 2005). Some of these changes can 270 
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influence the product’s response to different technological treatments, and hence its chilling and 271 
frozen stability. Studies  on chilling storage with special emphasis on microbiological aspects and 272 
the formation of biogenic amines (Ruiz-Capillas, Cofrades, Serrano, & Jiménez-Colmenero, 2004), 273 
and on frozen storage with special emphasis on lipid oxidation (Serrano, Cofrades, & Jiménez-274 
Colmenero, 2006) have shown that the presence of walnut is not a limiting factor for product 275 
stability.  276 
Restructured beef steak, like other foods, will normally be cooked prior to consumption. 277 
Heat treatment has a significant impact on the composition and physicochemical characteristics of 278 
final food products; indeed, it is well known that meat product composition (fat content, added non-279 
meat ingredients) and cooking techniques are among the factors most affecting the final quality 280 
attributes of the product. The influence of various cooking methods—grilling, conventional oven, 281 
microwave oven and pan-frying—on the composition and physicochemical characteristics of 282 
restructured beef steaks has been investigated by Serrano, Librelotto, Cofrades, Sánchez-Muniz and 283 
Jiménez-Colmenero (2007). No limitations were observed due to different cooking procedures 284 
(roasting, grilling and pan-frying) on the physicochemical characteristics of restructured steaks 285 
containing walnut. Despite their high polyunsaturated fat content, lipid oxidation of restructured 286 
beef steak containing walnut was low after all cooking procedures. The high lipid retention of 287 
walnut restructured steaks during cooking assures a healthy food profile at the moment of ingestion 288 
(Serrano et al., 2007). More specific studies have been conducted on the effect of pan-frying in 289 
extra virgin olive oil on the fatty acid profile and fatty acid retention and thermal oxidation of 290 
restructured functional steaks (Librelotto et al., 2008) and on long frozen storage stability of the 291 
same product (Librelotto, Bastida, Zulin-Botega, Jiménez-Colmenero, & Sánchez-Muniz, 2009). 292 
This culinary technique produced fried steaks with low lipid alteration (oxidative and hydrolytic). 293 
Moreover, the atherogenic and thrombogenic indices of these pan-fried restructured steaks were 294 
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much lower than those of reduced- or medium-fat counterparts, so that the meat was highly 295 
acceptable from a nutritional and a CVD point of view (Librelotto et al., 2009).  296 
 297 
7.2 Frankfurters 298 
Alongside the research on restructured steaks, several studies have been conducted to 299 
address the technological challenge also posed by reformulation (design and development) of meat 300 
products based on gel/emulsion systems. These have assessed how the presence of different 301 
amounts of walnut (7, 14 and 21%) influences the characteristics (physicochemical, morphological 302 
and sensory) of meat emulsion products, in this case frankfurters. Morphology, textural parameters  303 
(hardness, cohesiveness and chewiness), fat- and water-binding properties and colour were all 304 
influenced by the level of walnut addition. Generally speaking, products with added walnut have 305 
presented sensory attributes acceptable to consumers (Ayo, Solas, Carballo, & Jiménez-Colmenero, 306 
2004; Carballo, Ayo, & Jiménez-Colmenero, 2003). In order to limit sodium levels, various studies 307 
have been conducted to assess the effect of several salt levels on products containing walnut (Ayo, 308 
Jiménez-Colmenero, Carballo, & Ruiz-Capillas, 2004) and analyse the use of transglutaminase in 309 
meat batters with different percentages of walnut and without salt (Cofrades et al., 2004b). On the 310 
basis of these results a study was conducted to compare products (with added walnut and no salt) 311 
formulated with combinations of transglutaminase and a number of non-meat ingredients 312 
(caseinate, KCl and wheat fibre) as salt replacers, with a product containing normal salt levels. The 313 
results suggest that some of the combinations assayed could be used to compensate for the absence 314 
of salt in the preparation of sausages containing walnut (Jiménez-Colmenero, Ayo, & Carballo, 315 
2005).  316 
We would note in a general way that the quality attributes of the meat products developed—317 
restructured steaks and frankfurters—containing 20 % of walnut were acceptable in terms of 318 
physicochemical and sensory properties and stability.  319 
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 320 
8. Nutritional profile of meat products with added walnut.  321 
The potential functional effect of walnut in meat-based functional foods derives from 322 
various constituents with health implications. Studies have been conducted both on restructured 323 
steaks (Serrano et al., 2005) and on frankfurters (Ayo et al., 2007) to determine how the walnut 324 
affects the nutritional profile. Compared with control products (0 % added walnut), the product 325 
with added walnut (20-25 %) presented a lower lysine/arginine ratio, larger quantities of MUFAs 326 
and ω-3 PUFAs (mainly α-linolenic acid), a lower ω-6/ω-3 PUFA ratio and a higher PUFA/SFA 327 
ratio. In restructured beef steak (13 % fat) formulated with 20 % added walnut, around 90 % of the 328 
fat content came from walnut; MUFAs and PUFAs together accounted for almost 90 % of total 329 
fatty acids, with ω-6/ω-3 PUFA < 4 and PUFA/SFA > 6.5 (Table 1). The addition of 20 % walnut 330 
also furnished around 1 % of dietary fibre. Energy content was 99 kcal/100g (414.2 kJ/100g) in the 331 
control sample (1.6 % fat content, no walnut added) and 213 kcal/100 g (891.2 kJ/100g) in the 332 
walnut (20 %) enriched product (14.5 % fat content), approximately 62 % of energy from fat. 333 
Replacement of raw meat material by walnut reduced the cholesterol content and increased (more 334 
than 400 fold) the amount of γ-tocopherol. Meat products with added walnut could be good sources 335 
of manganese, iron, copper, potassium and magnesium, supplying high percentages (15-40 %) of 336 
the daily recommended intakes for these minerals.  337 
The γ-tocopherol content of restructured meat products is of particular interest as the 338 
exposure biomarker chosen in the intervention study to assess the functionality of the products 339 
designed—walnut-enriched steaks containing over 4000 µg γ-tocopherol/100g (Table 1), walnut-340 
enriched sausages containing 4980 µg γ-tocopherol/100g and walnut-free steaks containing ca. 19 341 
µg γ-tocopherol/100g (Olmedilla-Alonso, Granado-Lorencio, Herrero-Barbudo, Blanco-Navarro, & 342 
Sánchez-Muniz, 2005; Olmedilla-Alonso et al., 2006).  343 
 344 
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9. Assessing the effect of meat-based functional products on cardiovascular disease risk. 345 
A 5-week randomized, placebo-controlled crossover study was conducted on subjects at risk 346 
of CVD (n=25) to assess the functional effect of consumption of restructured steaks and 347 
frankfurters containing 20 % walnut. For five weeks, instead of meat and meat derivates the 348 
volunteers consumed five meat products (4 steaks and 1 sausage, with or without added walnut) per 349 
week (150 g meat product/ helping). The habitual consumption of a mixed diet (no avoidance of 350 
any groups) was required. In terms of equivalent walnut consumption, that would be 30 g 351 
walnut/steak and 16 g walnut/helping of sausages. This means consuming 136 g of walnuts per 352 
week, giving an average intake of 19.4 g walnuts/day, which is ca. 70 % of the amount of walnuts 353 
suggested by the (FDA, 2004; FDA, 2009).  354 
Men and women were selected who had at least four CVD risk factors as identified by the 355 
WHO/FAO in their report on prevention of chronic diseases through diet (WHO, 2003). Inclusion 356 
criteria were: age (men: 45-65, women: 50-70 years and postmenopausal), overweight (BMI > 25 357 
and < 34.90 kg/m2), serum cholesterol > 220 and < 290 mg/dl, and at least one of the following 358 
features: smoking habit and/or blood pressure ≥ 140/90 mm Hg.  359 
The bioavailability of walnut components contained in the new products was assessed 360 
beforehand by means of a postprandial (single-dose) study in three volunteers using γ-tocopherol as 361 
an exposure marker. The reason for choosing this compound was that consumption of the meat 362 
product with added walnuts supplies significantly more γ-tocopherol (ca. 29 mg γ-tocopherol per 363 
week) than is normally supplied by our diet (Olmedilla-Alonso et al., 2005). Consumption of a 364 
restructured meat product caused an increase in γ-tocopherol in the triglyceride-rich lipoprotein 365 
fraction during the postprandial period only when walnuts were added. The increase peaked 6 hours 366 
after intake (time evaluated: 6 h). This provides in vivo evidence of the efficacy of walnut-enriched 367 
restructured meat products as a vehicle for bioactive substances, e.g. γ-tocopherol (Olmedilla-368 
Alonso et al.,  2008). 369 
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The functional effects were assessed using clinicaly relevant and related biomarkers of CHD: 370 
1) biomarkers of function: a) used in clinical practice: cholesterol (total, LDL-cholesterol and 371 
HDL-cholesterol), triacylglycerols, blood pressure and homocysteine; b) biomarkers sensitive to 372 
dietary changes and associated with CVD risk: folic acid, vitamins B6 and B12, α-tocopherol, serum 373 
γ-tocopherol, and platelet function test; c) other biomarkers: eicosanoids (e.g. Thromboxan A2, 374 
prostacyclin I2, leukotrien B4), Lp(a), apolipoprotein (Apo) A1, Apo B, platelet aggregation, 375 
inflammation markers (PCR and adhesion of monocytes VCAM and ICAM), lipid peroxidation 376 
(oxidized LDL, LPO), antioxidant status based on the activity of catalase (CAT), superoxide 377 
dismutase (SOD), total glutathione, reduced glutathione (GSH) and oxidized glutathione (GSSG) in 378 
red cells and the activities of paraoxonase (PON-1), aryilesterase in plasma; 2) biomarkers of 379 
CHD/CVD risk: total cholesterol, LDL-cholesterol and systolic and diastolic blood pressure. 380 
Although several markers have been proposed to study the relationship between diet and 381 
CVD, (Aggett et al., 2005; Contor & Asp, 2004; Mensink et al., 2003), only LDL-cholesterol and 382 
blood pressure are well-established markers generally accepted as related to changes in risk of 383 
CVD, although they are not direct measures of CHD incidence. Diet-related changes in cholesterol 384 
and blood pressure could allow claims for enhanced function and would also support disease risk 385 
reduction claims.  386 
The effect of the consumption of restructured meat products with and without added 387 
walnuts was evaluated by means of the above mentioned biomarkers of function and CHD-related 388 
risk. Table 2 shows the ones most commonly used in clinical practice (along with γ-tocopherol as 389 
exposure biomarker). On comparing concentrations after the diet containing walnut-enriched meat 390 
products with the baseline (habitual mixed diet), there was a decrease in total cholesterol (10.7 391 
mg/dl), LDL-cholesterol (7.6 mg/dl) and body weight (0.5 kg) and a slight decrease in systolic 392 
pressure, as well as an increase in γ-tocopherol (8.9 µg/dl). Other biomarkers such as 393 
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homocysteine, folate and vitamins B6 and B12 remained within normal ranges, as did platelet 394 
function (measured as obturation time) (Olmedilla-Alonso et al., 2008) 395 
 HDL-cholesterol, fasting triacylglycerols and plasma homocysteine are established 396 
examples of markers sensitive to dietary factors and have been validated methodologically, but it is 397 
not yet clear to what extent changes in these markers reflect improved state of health and well being 398 
and performanceand reduction of disease risk. For haemostatic function and oxidative damage, 399 
there is a need to develop and validate markers of improved state of health and disease risk 400 
reduction that are sensitive to dietary changes (Aggett et al., 2005).  401 
In this study we expected no changes in body weight, as the dietary intervention only 402 
involved the substitution of meat sources in the diet. However, three volunteers out of 25 registered 403 
small but significant reductions in body weight with the consumption of walnut-enriched meat with 404 
respect to that of the low-fat restructured meat. Weight loss has also been reported in other studies 405 
likewise involving a control group and adjusting for energy (Iwamoto et al., 2002), and in a recent 406 
prospective study in which increased nut consumption was not associated with greater body weight 407 
gain during eight years of follow-up in healthy middle-aged women; instead, it was associated with 408 
a slightly lower risk of weight gain and obesity (Bes-Rastrollo et al., 2009). 409 
Studies have been conducted comparing the effect of consumption of walnut-enriched 410 
restructured steak and frankfurter with that of consumption of low-fat meat products on different 411 
markers of antioxidant status (Canales et al. , 2007) and of platelet aggregation and thrombogenesis 412 
(Canales et al., 2009). This intervention study was the first to evaluate the effect on those 413 
parameters of the intake of meat products with added walnut in subjects at high risk of developing 414 
CHD. Erythrocyte catalase (CAT), superoxide dismutase (SOD), total glutathione, reduced 415 
glutathione (GSH), oxidized glutathione (GSSG), lipid peroxidation (LPO), and serum uric acid 416 
and paraoxonase-1 (PON-1) were all tested in increased-CHD-risk individuals consuming meat 417 
products with added walnut with respect to the same individuals consuming control products.  418 
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Present data clearly show that the intake, 5 times per week, of meat products with added 419 
walnut for 5 weeks increased concentrations/activities of several antioxidant defence biomarkers, 420 
such as CAT, SOD, PON1, total glutathione, GSH and GSSG in those volunteers (Canales et al., 421 
2007) (Figures 1 and 2). Natural defence against ROS involves a number of enzymatic and non 422 
enzymatic antioxidant mechanisms (Sies, 1991). The particular composition of walnuts (and thus, 423 
of walnut enriched meat), which are rich in antioxidant compounds such as vitamin E, α-424 
tocopherol, γ-tocopherol, δ-tocopherol, folic acid and vitamin C (Nus et al., 2004; Olmedilla-425 
Alonso et al., 2006; Ravai, 1995; USDA, 2005), seems to be responsible for improving the 426 
antioxidant status of study participants.  427 
The intake of meat products with added walnut increased PON-1 activity irrespective of 428 
HDL-C levels, which were not affected by the treatment. This corroborates results of other studies 429 
(Almario, Vonghavaravat, Wong, & Kasim-Karakas, 2001). The increase in PON-1 concentrations 430 
is presumably a consequence of the intake of a relatively large amount of PUFAs, counterbalanced 431 
by the consumption of nut antioxidants. Many other authors have investigated the influence of diet 432 
on PON-1 activity, but available results are controversial. The consumption of meat products with 433 
added walnut induced a reduction of ~34% LPO concentration in erythrocytes as compared to 434 
approximately ~8% in the control products. These results suggest that lipid peroxidation is not 435 
increased by meat products with added walnut consumption despite their higher PUFA content. 436 
Haque et al. (2003) found that an aqueous extract of walnut reduced the LPO content in liver and 437 
kidney of mice induced by chemotherapy toxicity.  438 
Platelet aggregation, plasma thromboxane (TX) A2 (measured as TXB2), prostacyclin I2 439 
(measured as 6-keto-PGF1α) production and the TXB2/6-keto-PF1α ratio were determined at 440 
baseline and at wk 3 and 5 for the two dietary periods (Canales et al., 2009). As indicated, the diet 441 
including meat products with added walnut contained lower SFA and higher PUFA concentrations 442 
and presented a more favourable ω-6/ω-3 ratio than the diet including control meat products, which 443 
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accounts for the larger variations in maximum aggregation values observed at week 5 [9.62 ± 0.67 444 
to 8.28 ± 0.56 cm/5 min (p<0.05) in walnut enriched meat versus 10.35 ± 0.52 to 10.30 ± 0.66 cm/5 445 
min (p>0.05) in control meat] (Canales et al., 2009). The lower linoleic to linolenic acid ratio of the 446 
diet including products with added walnut, together with other walnut compounds, should affect 447 
platelet reaction capacity (Chan  et al., 1993). At week 5, significant differences (P<0.05) between 448 
treatments were found for maximum aggregation rate, TXB2 values and the TXB2/6-keto-PF1α 449 
ratio. The effects on TXB2 and the TXB2/6-keto-PF1α ratio were time-course dependent (Canales et 450 
al., 2009).  451 
Platelet aggregation is modulated by the production of TXA2 and PGI2. An optimal balance 452 
of TXA2/PGI2 may be important in the prevention of thrombotic conditions. The diet including 453 
walnut-enriched meat products contains a lower concentration of SFA and presents 454 
linoleic/linolenic and ω-6/ω-3 PUFA ratios that are 2.5 times lower than those of the diet including 455 
non-walnut-enriched meat products, which would account, at least partially, for the results. 456 
Proanthocyanidins, naturally occurring plant metabolites commonly found in fruits, vegetables, 457 
nuts, seeds, flowers and bark (Bagchi et al., 1997; Fine, 2000), form part of a specific group of 458 
polyphenolic compounds called flavonoids (Bravo, 1998). These compounds are reported to have 459 
anti-inflammatory and vasodilatory properties (Bagchi et al., 1997; Bagchi et al., 1998), to inhibit 460 
lipid peroxidation, platelet aggregation and capillary permeability and to affect, among others, the 461 
phospholipase A2, cyclooxigenase and lipoxygenase enzyme systems (Bagchi et al., 1997; Bagchi 462 
et al., 1998; Murray & Pizzorno, 1999; Robert et al., 1990). Moreover, it has been suggested that 463 
tocopherol may reduce thrombogenesis (Robert et al., 1990; Szczeklik, Grylewski, Domagala, 464 
Dworski, Basista, 1985).  465 
However, the inter-individual variability of these findings was also striking (Canales et al., 466 
2009; Nus et al., 2007), and genetic factors may influence the results. It was therefore hypothesized 467 
that volunteers at increased CHD risk having different polymorphisms in CVD gene candidates 468 
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respond differently to the intake of restructured beef steaks and sausages containing walnuts in 469 
terms of platelet aggregation, TXA2, PGI2 and the thrombogenic ratio (TXA2/PGI2), and 470 
antioxidant status (e.g. erythrocyte CAT, SOD, total glutathione, GSH and GSSG). To this end the 471 
population that was defined was screened for polymorphisms for APOA4 (Canales et al., 2010) and 472 
PON-1 genes (unpublished data). Although modifications in dietary cholesterol and saturated fat 473 
affect plasma lipids differently in carriers of each APOA4 variant (Herron, Lofgren, Adiconis, 474 
Ordovás, & Fernández, 2006; Hubacek et al.,  2007), to date there have been no studies on the 475 
effect of an APOA4 polymorphism on thrombogenesis. Moreover, no data are available on the 476 
effect of APOA4 polymorphism and the varied response to walnut consumption in individuals at 477 
increased CVD risk.  478 
PON-1, a HDL-bound enzyme, may be involved in lipoprotein-phospholipid metabolism 479 
and may also inhibit lipid peroxide generation in LDL (Canales & Sánchez-Muniz, 2003; Mackness 480 
et al., 1998; Nus, Sánchez-Muniz, & Sánchez-Montero, 2006). Available data suggest that PON-1 481 
is likely to be more active in the absence of antioxidants. PON-1 exists in 2 major polymorphic 482 
forms which include the replacement of glutamine (Q) by arginine (R) at position 192 (Adkins, 483 
Gan, Mody, & La Du, 1993) and of leucine (L) by methionine (M) at position 55 (Garin et al., 484 
1997). It has been postulated that the ability of HDL to protect LDL against peroxidation in vitro is 485 
significantly lower in HDL particles from PON-1-R192 (Aviram et al., 2000) than in PON-1-Q192 486 
carriers.  487 
Although the results have not yet been fully evaluated and discussed, the data suggest that 488 
the decrease of TXB2 levels and the TXB2/6-keto-PGF1α ratio in APOA4-2 with respect to 489 
APOA4-1 carriers after the 5-wk treatment was significantly greater in the diet including walnut-490 
enriched products than in the diet including non-walnut-enriched counterparts. Also, our results 491 
revealed a different response of antioxidant status in meat products (walnut-enriched vs. non-492 
walnut-enriched) depending on PON-1 polymorphisms. Unpublished data suggest that the changes 493 
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in antioxidant status markers at week 5 in meat products with added walnut with respect to the 494 
control were greater in PON-1(QQ)192 polymorphism carriers than in PON-1 (QR+RR)192 495 
carriers (data not shown). 496 
 497 
10. Concluding remarks 498 
In functional foods, if in addition to achieving quality attributes comparable to those of any 499 
other product we wish to assure the presence, absence or reduction of a nutrient or other substance 500 
that we know to produce a potential beneficial effect—which has to be established with generally 501 
accepted scientific data—then design and development are essential steps.  502 
The design and development of potentially functional meat products based on the addition 503 
of walnut has been addressed as part of a project whose goals range from the design and 504 
development of meat products in which nutrients associated with CVD risk are qualitatively and 505 
quantitatively modified to the study of bioavailability and the effect of consumption on 506 
intermediate markers of CVD risk in humans. By using technological strategies in the 507 
reformulation of meat matrixes, it has been possible to achieve products with a specific 508 
composition (less animal fat and sodium and fortified with various bioactive compounds) which 509 
present acceptable quality attributes in terms of physicochemical and sensory properties and 510 
stability.  511 
Our assessment of the effect of meat-based functional products on subjects at CVD risk 512 
suggests that since regular consumption of meat products containing walnuts produces (i) a 513 
reduction in intermediate clinical markers of CHD (such as total and LDL cholesterol), (ii) an 514 
improvement in antioxidant status and (iii) a reduction in thrombogenesis markers, they may be 515 
considered products that meet the requirements of functional foods for subjects at high risk of CVD 516 
like the ones included in the present study. As the walnut was used whole, the observed effects may 517 
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be associated with its peculiar blend of nutrient and phytochemical compounds but cannot be 518 
related to any individual ingredient.  519 
Genotyping studies in ample populations should be performed in order to ascertain the 520 
actual target subjects for this functional meat. 521 
In view of the observed benefits accruing from the consumption of walnut-enriched meat, 522 
meat industries should seriously consider making and marketing meat products of this kind, and 523 
consumers should not hesitate to consume them. Nonetheless, more studies are still desirable to test 524 
the effect of long-term consumption of this kind of meat products.  525 
 526 
Acknowledgements 527 
This research was supported under projects AGL2001-2398-C03 and Consolider-Ingenio 2010. 528 
CARNISENUSA CSD2007-00016. Plan Nacional de Investigación Científica, Desarrollo e 529 
Innovación Tecnológica (I+D+I), Ministerio de Ciencia y Tecnología. Spain. Thanks are due to “La 530 




Adkins, S., Gan, K. N., Mody, M., & La Du, B. N. (1993). Molecular basis for the polymorphic 535 
forms of huma serum paraoxonase/arylesterase: glutamine or arginine at position 191, for 536 
the respective A or B allozymes. The American Journal of Human Genetics, 52, 598-608. 537 
Aggett, P. J., Antoine, J-M., Asp, N-G., Bellisle, F., Contor, L., Cummings, J. H., Howlett, J, et al. 538 
(2005). PASSCLAIM. Process for the assessment of scientific support for claims on foods. 539 
Consensus on criteria. European Journal of Nutrition, (Suppl.1), 44, 1-31. 540 
 24
Almario, R.U., Vonghavaravat, V., Wong, R., & Kasim-Karakas, S. E. (2001). Effects of walnut 541 
consumption on plasma fatty acids and lipoproteins in combined hyperlipidemia. American  542 
Journal of Clinical Nutrition, 74, 72-79.  543 
Arihara, K. (2006). Strategies for designing novel functional meat products. Meat Science, 74, 219-544 
229. 545 
Asp, N.G., Cummings, J.H., Howlett, J., Rafter, J., Riccardi, G., & Westenhoefer, J. (Guest 546 
Editors) (2004). Process for the Assessment of Scientific Support for Claims on Foods. 547 
Phase Two: Mowing Forward. European  Journal of Nutrition, 43(supl.2), 1-30. 548 
 Aviram, M., Hardak, E., Vaya, J., Mahmood, S., Milo, S., Hoffman, A., Billicke, S., Draganov, D., 549 
& Rosenblat, M. (2000). Human serum paraoxonase (PON-1) Q and R selectively decrease 550 
lipid peroxides in human coronary and carotid arteriosclerotic lesions. Circulation, 101, 551 
2510–7. 552 
Ayo, J., Carballo, J., Serrano, J., Olmedilla-Alonso, B., Ruiz-Capillas, C., & Jiménez-Colmenero, 553 
F. (2007). Effect of total replacement of pork backfat with walnut on nutritional profile of 554 
frankfurters. Meat Science, 77, 173-181. 555 
Ayo, J., Jiménez Colmenero, F., Carballo, J., & Ruiz-Capillas, C. (2004). Physicochemical 556 
properties of meat batters with added walnut: Effect of salt levels. Proceeding of the 50th 557 
International Congress Meat Science and Technology, Helsinki Finland. 558 
Ayo, J., Solas, M. T., Carballo, J., & Jiménez-Colmenero, F. (2004). Microestructura de emulsiones 559 
cárnicas: efecto de la incorporación de nuez y de la aplicación de altas presiones. 560 
Proceedings of the X Congreso Anual de Ciencia y Tecnología de los Alimentos. 561 
Universidad Complutense Madrid. Madrid. Spain. 562 
Bagchi, D., Garg, A., Krohn, R. L., Bagchi, M., Bagchi, D. J., Balmoori, J., & Stohs, S. J. (1998). 563 
Protective effect of grape proanthocyanidins and selected antioxidants against TPA-induced 564 
 25
hepatic and brain lipid peroxidation and DNA fragmentation, and peritoneal macrophage 565 
activation in mice. Gen Pharmacology, 30, 771-776. 566 
Bagchi, D., Garg, A., Krohn, R. L., Bagchi, M., Tran, M. X., & Stohs, S. J. (1997). Oxygen free 567 
radical scavenging abilities of vitaminC and E, and a grape seed proanthocyanidin extract in 568 
vitro. Research Communications in Molecular Pathology and Pharmacology, 95, 79-189. 569 
Banel, D. K., & Hu, F. B. (2009). Effects of walnut consumption on blood lipids and other 570 
cardiovascular risk factors: a meta-analysis and systematic review. American  Journal of 571 
Clinical Nutrition, 90, 56-63. 572 
Bes-Rastrollo, M., Wedick, N., Martínez-González, M. A., Li, T. Y., Sampson L., & Hu, F. B. 573 
(2009). Prospective study of nut consumption, long-term weight change, and obesity risk in 574 
women. American  Journal of Clinical Nutrition, 89, 1913-1919. 575 
Bravo, L. (1998). Polyphenols: chemistry, dietary sources, metabolism, and nutritional 576 
significance. Nutrition Review, 56, 317-333.  577 
Canales, A., Bastida, S., Librelottto, J., Nus, M., Sánchez-Muniz, F. J., & Benedí, J. (2009). Platelet 578 
aggregation, eicosanoid production and thrombogenic ratio in individuals at high 579 
cardiovascular risk consuming meat enriched in walnut paste. A crossover, placebo-580 
controlled study. British Journal of Nutrition, 102,134-141.  581 
Canales, A., Benedí, J., Nus, M., Librelotto, J., Sánchez-Montero, J.M., & Sánchez-Muniz, F. J. 582 
(2007). Effect of walnut-enriched restructured meat in the antioxidant status of 583 
overweight/obese senior subjects with at least one extra CHD-risk factor. Journal of the 584 
American College of Nutrition, 26, 225-232.  585 
Canales, A., Benedí, J., Bastida, S., Corella, D., Guillén, M., Librelottto, J., Nus, M., & Sánchez-586 
Muniz, F. J. (2010). ApoA4 polymorphism modifies the effect of consuming meta enriched 587 
in walnut paste on thrombogenesis. A controlled cross-over study. Nutrición Hospitalaria 588 
(MS# 4504). 589 
 26
Canales, A., & Sánchez-Muniz, F. J. (2003). Paraoxonase, something more than an enzyme?. 590 
Medicina Clinica (Barcelona), 121, 537–548. 591 
Carballo, J., Ayo, J., & Jiménez Colmenero, F. (2003). Efecto de la incorporación de nuez en las 592 
propiedades físico-químicas de emulsiones cárnicas. Proceedings of the II Congreso 593 
Nacional de Ciencia y Tecnología de los Alimentos. Universidad Miguel Hernández 594 
(UMH). Orihuela, Spain. Editado por UMH, Vol. II, 469-472. 595 
Chan, J. K., McDonald, B. E., Gerrard, J. M., Bruce, V. M., Weaver, B. J., & Holub, B. J. (1993). 596 
Effect of dietary alpha-linolenic acid and its ratio to linoleic acid on platelet and plasma 597 
fatty acids and thrombogenesis. Lipids, 28, 811-817. 598 
Cofrades, S., Serrano, A., Ayo, J., Carballo, J., Ruiz-Capillas, C., & Jiménez-Colmenero, F. 599 
(2004b). Effect of walnut, microbial transglutaminase and storage time on the water and fat 600 
binding capacity of salt-free beef batters. Proceeding of the 50th International Congress 601 
Meat Science and Technology, Helsinki Finland. 602 
Cofrades, S., Serrano, A., Ayo, J., Solas, M. T., Carballo, J., & Jiménez-Colmenero, F. (2004a). 603 
Restructured beef with different proportions of walnut as affected by meat particle size. 604 
European Food Research Technology, 218, 230-236. 605 
Contor, L., & Asp, N. G. (2004). Process for the assessment of scientific support for claims on 606 
foods. Phase two: moving forward. European  Journal of Nutrition, 43(sup.2), II/3-II/6. 607 
Diplock, A. T., Aggett, P. J., Ashwell, M., Bornet, F., Fern, E. B., & Roberfroid, M. B. (1999). 608 
Scientific concepts of functional foods in Europe: Consensus Document. British Journal of 609 
Nutrition, 81 (suppl.1), S1-S27.  610 
FDA (2003). Food and Drug Administration. Office of Nutritional Products, Labelling and Dietary 611 




10.htm      Accessed 06/22/2009 615 
FDA (2004). Moves Forward on Qualified Healht Claims.  616 
 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108273.htm. 617 
Accessed 06/18/2009 618 
FDA (2009). Food and Drug Administration. Office of Nutritional Products, Labeling and Dietary 619 
Supplements Qualified Health Claims Subject to Enforcement Discretion. Walnuts and 620 
heart disease.  621 
http://www.fda.gov/Food/LabelingNutrition/LabelClaims/QualifiedHealthClaims/ucm0739622 
92.htm  Accessed 06/18/2009 623 
Feldman, E. B. (2002). The scientific evidence for a beneficial health relationship between walnuts 624 
and coronary heart disease. Journal of  Nutrition, 132, 1062S-1101S.  625 
Fine, A. M. (2000). Oligomeric proanthocyanidin complexes: History, structure, and 626 
phytopharmaceutical applications. Alternative Medicinal Review, 5:, 44-151.  627 
Fitó, M., Guxens, M., Corella, D., Sáez, G., Estruch, R., de la Torre, R., Francés, F., Cabezas, C., 628 
López-Sabater, M.C, Marrugat, J., García-Arellano, A., Arós, F., Ruiz-Gutierrez, V., Ros, 629 
E., Salas-Salvadó, J., Fiol, M., Solá, R., & Covas, M. I. for the PREDIMED Study 630 
Investigators. (2007). Effect of a traditional Mediterranean diet on lipoprotein oxidation: a 631 
randomized controlled trial. Archives of Internal Medicine, 167, 195-1203.  632 
Fraser, G. E., Sabaté, J., Beeson, W. L., & Strahan, T. M. (1992). A possible protective effect of 633 
nut consumption on risk of coronary heart disease: the Adventist Health Study. Archives of 634 
Internal Medicine, 152, 1416-1424. 635 
Garin, M. C., James, R. W., Dussoix, P., Blanché, H., Passa, P., Froguel, P., & Ruiz, J. (1997). 636 
Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of 637 
 28
the enzyme. A possible link between the paraoxonase gene and increased risk of 638 
cardiovascular disease in diabetes. Journal of Clinical Investigation, 99, 62-66. 639 
Haque, R., Bin-Hafeez, B., Parvez, S., Pandey, S., Sayeed, I., Ali, M., & Raisuddin, S. (2003). 640 
Aqueous extract of walnut (Juglans regia L.) protects mice against cyclophosphamide-641 
induced biochemical toxicity. Human Experimental Toxicology, 22, 473-480. 642 
Herron, K. L., Lofgren, I. E., Adiconis, X., Ordovas, J. M., & Fernandez, M. L. (2006). 643 
Associations between plasma lipid parameters and APOC3 and APOA4 genotypes in a 644 
healthy population are independent of dietary cholesterol intake. Atherosclerosis, 184, 113-645 
120.  646 
Hubacek, J. A., Bohuslavova, R., Skodova, Z., Pitha, J., Bobkova, D., & Poledne, R. (2007). 647 
Polymorphisms in the APOA1/C3/A4/A5 gene cluster and cholesterol responsiveness to 648 
dietary change. Clinical Chemistry and Laboratory Medicine, 45, 316-320. 649 
INE (Instituto Nacional de Estadística). (1994). Encuesta de Presupuestos Familiares, 1990-1991. 650 
Vol. 2. Madrid. 651 
Iwamoto, M., Imaizumi, K., Sato, M., Hirooka, Y., Sakai, K., Takeshita, A., & Kono M. (2002). 652 
Serum lipid profiles in Japanese women and men during consumption of walnuts. European 653 
Journal of  Clinical Nutrition, 56, 629-637. 654 
Iwamoto, M., Sato, M., Kono, M,. Hirooka, Y., Sakai, K., Takeshita, A., & Imaiuzumi, K. (2000). 655 
Walnuts lower serum cholesterol in Japanease men and women. Journal of Nutrition, 130, 656 
171-176. 657 
Jiménez-Colmenero, F. (2007a). Meat based functional foods. In: Hui Y. H., Associate editors, 658 
Chandan et al.(eds), Handbook of Food Products Manufacturing. (pp. 989-1015). New 659 
Jersey: John Wiley & Son, Inc.  660 
 29
Jiménez-Colmenero, F. (2007b). Healthier lipid formulation approaches in meat based functional 661 
foods. Technological options for replacement of meat fats by non-meat fats. Trends in Food 662 
Science and Technology, 18, 567-578. 663 
Jiménez-Colmenero, F., Ayo, J., & Carballo, J. (2005). Physicochemical properties of low sodium 664 
frankfurter with added walnut: Effect of transglutaminase combined with caseinate, KCl and 665 
dietary fibre as salt replacers. Meat Science, 69, 781-788.  666 
Jiménez-Colmenero, F., Carballo, J., & Cofrades, S. (2001). Healthier meat and meat products: 667 
Their role as functional foods. Meat Science, 59, 5-13. 668 
Jiménez-Colmenero, F. Reig., M., & Toldrá, F. (2006). New approaches for the development of 669 
functional meat products. In: Nollet L. M. L. Toldrá, F. (eds). Advanced Technologies for 670 
Meat Processing. pp. 275-308, Boca Raton London, New York: Taylor & Francis Group. 671 
Jiménez-Colmenero, F., Serrano, A., Ayo, J., Solas, M. T. Cofrades, S., & Carballo, J. (2003). 672 
Physicochemical and sensory characteristics of restructured beef steak with added walnuts. 673 
Meat Science, 65, 1391-1397. 674 
Librelotto, J., Bastida, S., Serrano, A., Cofrades, S., Jiménez-Colmenero, F., & Sánchez-Muniz, F. 675 
J. (2008). Changes in fatty acids and polar material of restructured low-fat or walnut-added 676 
steaks pan-fried in olive oil. Meat Science,  80, 431-441. 677 
Librelotto, L., Bastida, S., Zulin-Botega, D., Jiménez-Colmenero, F., & Sánchez-Muniz, F. J. 678 
(2009).  Effect of long frozen storage in the formation of triglyceride alteration compounds 679 
of pan-fried functional restructured beef steaks. Meat Science, 81, 726-730. 680 
Mackness, M. I., Mackness, B., Durrington, P. N., Fogelman, A. M., Berliner, J., Lusis, A. J., 681 
Navab, M., Shih, D., & Fonarow, G. C. (1998). Paraoxonase and coronary heart disease. 682 
Current Opinion in Lipidology, 9, 319-24. 683 
MAPA (2003). Ministerio de Agricultura, Pesca y Alimentación. www.mapya.es. Accessed 684 
03/03/2004. 685 
 30
Mensink, R. P., Aro, A., Den Hond, E., German, J. B., Griffin, B. A., ter Meer, H. U., Mutanen, M., 686 
Pannemans, D., & Stahl, W. (2003). PASSCLAIM. Diet-related cardiovascular disease. 687 
European Journal of Nutrition, 42 (suppl.1), 6-27. 688 
Muguerza, E., Gimeno, O., Ansorena, D., & Astiasarán, I. (2004). New formulations for healthier 689 
dry fermented sausages: a review. Trends in Food Science and Technology, 15, 452-457. 690 
Murray, M. & Pizzorno, J. (1999). Procyanidolic oligomeriers. In: Murray M. Pizzorno J, eds. The 691 
Textbook of Natural Medicine. (pp. 899-902). 2nd ed. London: Churchill Livington. 692 
Nus, M., Frances, F., Librelotto, J., Canales, A., Corella, D., Sanchez-Montero, J. M., & Sanchez-693 
Muniz, F. J. (2007). Arylesterase activity and antioxidant status depend on PON1-Q192R 694 
and PON1-L55M polymorphisms in subjects with increased risk of cardiovascular disease 695 
consuming walnut-enriched meat. Journal of Nutrition, 137, 1783-1788.  696 
Nus, M., Ruperto, M., & Sánchez-Muniz, F. J. (2004). Nuts, cardio and cerebrovascular risks. A 697 
Spanish perspective. Archivos Latinoamericanos de Nutrición, 54, 137-148. 698 
Nus, M., Sánchez-Muniz, F. J., & Sánchez-Montero, J. M. (2006). A new method for the 699 
determination of arylesterase activity in human serum using simulated body fluid. 700 
Atherosclerosis, 188, 155–159. 701 
Olmedilla-Alonso, B., Granado-Lorencio, F., Herrero-Barbudo, C., Blanco-Navarro, I., & Sánchez-702 
Muniz, F. J. (2005). Productos cárnicos funcionales preparados con nuez. Evaluación del 703 
efecto funcional. (Parte 3). CTC Alimentación, 24, 37-41. 704 
Olmedilla-Alonso, B., Granado-Lorencio, F., Herrero-Barbudo, C., & Blanco-Navarro, I. (2006). 705 
Nutritional approach for designing meat-based functional food products with nuts. Critical 706 
Review in Food Science and Nutrition, 46, 537-542.   707 
Olmedilla-Alonso, B., Granado-Lorencio, F., Herrero-Barbudo, C., Blanco-Navarro, I., Blázquez-708 
García, S., & Pérez-Sacristán, B. (2008). Consumption of restructured meat products with 709 
added walnuts has a colesterol-lowering effect in subjects at high cardiovascular risk: a 710 
 31
randomised, crossover, placebo-controlled study. Journal of the American College of 711 
Nutrition,  27, 342-348.    712 
Ravai, M. (1995). California walnuts. The natural way to healthier heart. Nutrition Today, 30, 173. 713 
Robert, L., Godeau, G., Gavignet-Jeannin, C., Groult, N., Six, C., & Robert, A. M. (1990) The 714 
effect of procyanidolic oligomers on vascular permeability. A study using quantitative 715 
morphology. Pathologie-Biologie (Paris), 38, 608-616. 716 
Ruiz-Capillas, C., Cofrades, S., Serrano, A., & Jiménez-Colmenero, F. (2004). Biogenic amines in 717 
restructured beef steaks as affected by added walnuts and chilling storage. Journal of Food 718 
Protection, 67, 607-609. 719 
Sabaté, J. (1993). Does nut consumption protect against ischaemic heart disease?. European 720 
Journal of  Clinical Nutrition, 47, S71-S75. 721 
Sabaté, J., Fraser, G.E., Burke, K., Knutsen, S., Bennett, H., & Lindsted, K.D. (1993). Effects of 722 
walnuts on serum lipids levels and blood pressure in normal men. The New England Journal 723 
of Medicine,  328, 603-607. 724 
Salas-Salvadó, J., Fernández-Ballart J., Ros, E., Martínez-González, M. A., Fitó, M., Estruch, R., et 725 
al., (2008) Effect of a Mediterranean diet supplemented with nuts on metabolic syndrome 726 
status. Archives of Internal Medicine, 168, 2449-2458. 727 
Salas-Salvadó, J., García-Arellano, A., Estruch, R., Márquez-Sandoval, F., Corella, D., et al. 728 
PREDIMED investigators. (2008). Components of the Mediterranean-type food pattern and 729 
serum inflammatory markers among patients at high risk for cardiovascular disease. 730 
European Journal of Clinical Nutrition, 62, 651-659. 731 
Sánchez-Muniz, F. (2004). Alimentos funcionales: carne y derivados cárnicos. Presente y 732 
perspectivas. In: F. Jiménez-Colmenero, F. J. Sánchez-Muniz, & B. Olmedilla (Eds). La 733 
Carne y Productos Cárnicos como Alimentos Funcionales. (pp. 39-58). Madrid. 734 
editec@red.   735 
 32
Serrano, A., Cofrades, S., & Jiménez-Colmenero, F. (2004). Transglutaminase as binding agent in 736 
fresh restructured beef steak with added walnuts. Food Chemistry, 85, 423-429. 737 
Serrano, A., Cofrades, S., & Jiménez-Colmenero, F. (2006). Characteristics of restructured beef 738 
steak with different proportions of walnut during frozen storage. Meat Science, 72, 108-115. 739 
Serrano, A., Cofrades, S., Ruiz-Capillas, C., Olmedilla-Alonso, B., Herrero-Barbudo, C., & 740 
Jiménez-Colmenero, F. (2005). Nutritional profile of restructured beef steak with added 741 
walnuts. Meat Science, 70, 647-654.  742 
Serrano, A., Librelotto, J., Cofrades, S. Sánchez-Muniz, F. J., & Jiménez Colmenero, F. (2007). 743 
Composition and physicochemical characteristics of restructured beef steaks containing 744 
walnuts as affected by cooking method. Meat Science, 77, 304-313. 745 
Sies, H. (1991). Oxidative stress: Oxidants and antioxidants. San Diego: Academic Press. 746 
Spanish Patent Application Nº solicitud 200300367. Productos cárnicos con compuestos bioactivos 747 
cardiosaludables incorporados mediante la adición de frutos secos, preferentemente nuez". 748 
Publicado por la Oficina Española de Patentes y Marcas (ES 2 216 699), 16 octubre 2004. 749 
Spanish Patent Application Nº solicitud 200400548. Mejora de la patente productos cárnicos con 750 
compuestos bioactivos cardiosaludables incorporados mediante la adición de frutos secos, 751 
preferentemente nuez”. Publicado por la Oficina Española de Patentes y Marcas (ES2 245 752 
218), 16 diciembre 2005. 753 
Szczeklik, A., Gryglewski, R. J., Domagala, B., Dworski, R., & Basista, M. (1985). Dietary 754 
supplementation with vitamin E in hyperlipoproteinemias: effects on plasma lipid 755 
peroxides, antioxidant activity, prostacyclin generation and platelet aggregability. Journal of 756 
Thrombosis and Haemostasis, 54, 425-430.  757 
Tyrovolas, S., & Panagiotakos, D. B. (2009). The role of Mediterranean type of diet on the 758 
development of cancer and cardiovascular disease, in the elderly: A systematic review. 759 
Maturitas, 65:122-130. 760 
 33
USDA (2005). U.S. Department of Agriculture, Agricultural Research Service. USDA National 761 
nutrient database for standard reference, Release 18. Nutrient Data Laboratory Home Page, 762 
2005, http://www.ars.usda.gov/ba/bhnrc/ndl  Accessed 12/10/2005. 763 
WCRF/AICR (1997). Food, nutrition and the prevention of cancer: a global perspective. World 764 
Cancer Research Fundation & American Institute for Cancer Research (USA). 765 
WHO (2003). Diet, Nutrition and the prevention of chronic diseases. WHO Technical report series 766 
916. Geneva (Switzerland). 767 
http://www.fao.org/docrep/005/AC911E/AC911E00.HTM#Contents Accessed 14/10/2004. 768 
WHO (2007). Cardiovascular diseases (CVDs). Fact sheet N° 317. February 2007. 769 
http://www.who.int/mediacentre/factsheets/fs317/en/index.html. Accessed 06/22/2009 770 
WHO (2009). Cardiovascular disease: prevention and control.  771 
http://www.who.int/dietphysicalactivity/publications/facts/cvd/en/.  Accessed 06/22/2009. 772 
